What are the NCCN treatment guidelines for relapsed/refractory primary mediastinal B-cell lymphoma (PMBCL)?

Updated: Sep 14, 2019
  • Author: Sonali M Smith, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

For treatment of relapse/refractory disease, NCCN guidelines recommends either pembrolizumab or following the guidelines for DLBCL. [20]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!